ScalmiBio minimizes side-effects of oncology and immuno-oncology antibody therapeutics.ScalmiBio’s proprietary SHIELD platform technology converts therapeutic antibodies into prodrugs activated specifically within tumor.Adverse events related to presence of specific targets in normal tissues limit dosing and efficacy of antibody therapies and prevent potential targets from being evaluated in clinical trials. SHIELD technolog...
ScalmiBio minimizes side-effects of oncology and immuno-oncology antibody therapeutics.ScalmiBio’s proprietary SHIELD platform technology converts therapeutic antibodies into prodrugs activated specifically within tumor.Adverse events related to presence of specific targets in normal tissues limit dosing and efficacy of antibody therapies and prevent potential targets from being evaluated in clinical trials. SHIELD technology restricts activity of antibody therapeutics to the tumor microenvironment to limit side effects, enable higher therapeutic doses, and allow broader use of multi-target combination treatments.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.